Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SCAR-CD44v6 T Cells for Treating Cancer
NCT04427449Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of 4SCAR-CD44v6 in cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Started Jun 2026; status: terminated.
02
Drugs
4SCAR-CD44v6
03
Conditions
cancer
Beyond the preview
Go deeper on NCT04427449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04427449.